TELCYTA® (Canfosfamide HCl) is a first in class investigational cancer cell-activated chemotherapeutic. It was designed to exploit the overexpression of glutathione S-transferase P1-1 (GST P1-1), an enzyme overexpressed in many human cancer cells. High levels of GST P1-1 are associated with a poor prognosis and resistance to certain chemotherapeutics.

Preclinical studies suggest the activation of TELCYTA occurs when GST P1-1 splits TELCYTA into two active fragments: a glutathione analog fragment and an active cytotoxic fragment. The cytotoxic fragment reacts with important cell components, including RNA, DNA and proteins, leading to cell death.

The glutathione analog fragment of TELCYTA may remain bound to GST P1-1, which may limit the ability of GST P1-1 to inactivate other cancer drugs. The results of preclinical studies suggest that TELCYTA is synergistic when combined with important chemotherapeutic drugs including platinums, taxanes and anthracyclines.

TELCYTA is a lead development candidate in Telik's pipeline. It was discovered through the application of our proprietary TRAP™ technology.

Completed TELCYTA Clinical trials include:

	ASSIST-1 (Assessment of Survival In Solid Tumors-1) A randomized Phase 3 study of TELCYTA versus liposomal doxorubicin or topotecan as third-line therapy in platinum-refractory or platinum-resistant ovarian cancer.
	ASSIST-3 (Assessment of Survival In Solid Tumors-3) A randomized Phase 3 study of TELCYTA plus Carboplatin versus liposomal doxorubicin as second-line therapy in platinum-refractory or platinum-resistant ovarian cancer.

	Phase 2 study of TELCYTA in combination with carboplatin in recurrent ovarian cancer
	Phase 2 study of TELCYTA in combination with liposomal doxorubicin in platinum-refractory or platinum-resistant ovarian cancer
	ASSIST-2 (Assessment of Survival In Solid Tumors-2) A randomized Phase 3 study of TELCYTA versus gefitinib as third-line therapy in locally advanced or metastatic non-small cell lung cancer.
	Phase 2 study of TELCYTA in combination with carboplatin and paclitaxel as first-line therapy in locally advanced or metastatic non-small cell lung cancer
	Phase 2 study of TELCYTA in combination with cisplatin as first-line therapy in locally advanced or metastatic non-small cell lung cancer
	Phase 2 study of TELCYTA in combination with docetaxel in platinum-resistant non-small cell lung cancer
	Phase 2 study of TELCYTA in refractory colorectal cancer
	Phase 2 study of TELCYTA in refractory metastatic breast cancer

Information on clinical trials is available at www.clinicaltrials.gov

Physicians and patients seeking additional information on TELCYTA® clinical trials may send Email to clinicaltrials@telik.com